CoChat
Sign Up
Cited by 42

The DOI matches its Crossref record; 43 of the 43 references it cites were found in a registry or an index.

Lipid and lipoprotein metabolism in microglia: Alzheimer’s disease mechanisms and interventions

Sprenger, Kayla G., Lietzke, Emma E., Melchior, John T., Bruce, Kimberley D.·2025·Journal of Lipid Research
DOI 10.1016/j.jlr.2025.100872PMC PMC12538436
Open this paper in CoChat — free account

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.jlr.2025.100872

Cites

43 of 43 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • ApoE4 causes dramatic lipid dysregulation in microglia under certain conditions, associated with altered lipid transport, accumulation of triglycerides and cholesterol esters, and accumulation of lipid droplets.

    “ApoE4 is known to cause dramatic lipid dysregulation in microglia under certain conditions that is associated with altered lipid transport, accumulation of triglycerides and cholesterol esters, and accumulation of lipid droplets [127].”

    From ApoE lipoproteins in the central nervous system under homeostasis and role in Alzheimer’s disease and related disorders (2026) · cites this paper as [127]

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Flagged first, then by citations

Research works printed but not linked: 140

  1. Rajan, 2021, Population estimate of people with clinical Alzheimer's disease and mild cognitive impairment in the United States (2020-2060), Alzheimers Dement, 17, 1966, 10.1002/alz.12362 · DOI · Paper page
  2. van Dyck, 2023, Lecanemab in early Alzheimer's Disease, N. Engl. J. Med., 388, 9, 10.1056/NEJMoa2212948 · DOI · Paper page
  3. Schindler, 2025, Anti-amyloid treatments: why we think they are worth it, Alzheimers Dement (N Y)., 11
  4. O'Brien, 1965, Fatty acid and fatty aldehyde composition of the major brain lipids in normal human gray matter, white matter, and myelin, J. Lipid Res., 6, 545, 10.1016/S0022-2275(20)39620-6 · DOI · Paper page
  5. Osetrova, 2024, Lipidome atlas of the adult human brain, Nat. Commun., 15, 4455, 10.1038/s41467-024-48734-y · DOI
  6. Soderberg, 1990, Lipid compositions of different regions of the human brain during aging, J. Neurochem., 54, 415, 10.1111/j.1471-4159.1990.tb01889.x · DOI
  7. Fitzner, 2020, Cell-Type- and brain-region-resolved mouse brain lipidome, Cell Rep., 32, 10.1016/j.celrep.2020.108132 · DOI
  8. He, 2025, Lipidome disruption in Alzheimer's disease brain: detection, pathological mechanisms, and therapeutic implications, Mol. Neurodegener., 20, 11, 10.1186/s13024-025-00803-6 · DOI · Paper page
  9. Alzheimer, 1995, An English translation of Alzheimer's 1907 paper, "Uber eine eigenartige Erkankung der Hirnrinde", Clin. Anat., 8, 429, 10.1002/ca.980080612 · DOI · Paper page
  10. Seferi, 2024, Distribution of lipid droplets in hippocampal neurons and microglia: impact of diabetes and exercise, Life Sci. Alliance, 7, 10.26508/lsa.202302239 · DOI · Paper page
  11. Sudwarts, 2023, Alzheimer's genes in microglia: a risk worth investigating, Mol. Neurodegener, 18, 90, 10.1186/s13024-023-00679-4 · DOI
  12. Fang, 2025, Structural insights into human ABCA7-mediated lipid transport, Structure, 33, 583, 10.1016/j.str.2024.12.015 · DOI
  13. Krasemann, 2017, The TREM2-APOE pathway drives the transcriptional phenotype of dysfunctional microglia in neurodegenerative diseases, Immunity, 47, 566, 10.1016/j.immuni.2017.08.008 · DOI · Paper page
  14. Lietzke, 2025, Synergistic reduction in interfacial flexibility of TREM2(R47H) and ApoE4 may underlie AD pathology, Alzheimers Dement, 21, 10.1002/alz.70120 · DOI
  15. Sangineto, 2023, Metabolic reprogramming in inflammatory microglia indicates a potential way of targeting inflammation in Alzheimer's disease, Redox Biol., 66, 10.1016/j.redox.2023.102846 · DOI · Paper page
  16. Baik, 2019, A breakdown in metabolic reprogramming causes microglia dysfunction in Alzheimer's Disease, Cell Metab., 30, 493, 10.1016/j.cmet.2019.06.005 · DOI · Paper page
  17. Sturno, 2025, Do microglia metabolize fructose in Alzheimer's disease?, J. Neuroinflammation, 22, 85, 10.1186/s12974-025-03401-x · DOI
  18. Sabogal-Guaqueta, 2023, Species-specific metabolic reprogramming in human and mouse microglia during inflammatory pathway induction, Nat. Commun., 14, 6454, 10.1038/s41467-023-42096-7 · DOI
  19. Keren-Shaul, 2017, A unique microglia type associated with restricting development of Alzheimer's Disease, Cell, 169, 1276, 10.1016/j.cell.2017.05.018 · DOI · Paper page
  20. Sastry, 1985, Lipids of nervous tissue: composition and metabolism, Prog. Lipid Res., 24, 69, 10.1016/0163-7827(85)90011-6 · DOI
  21. Svennerholm, 1968, Distribution and fatty acid composition of phosphoglycerides in normal human brain, J. Lipid Res., 9, 570, 10.1016/S0022-2275(20)42702-6 · DOI
  22. Scott-Hewitt, 2020, Local externalization of phosphatidylserine mediates developmental synaptic pruning by microglia, EMBO J., 39, 10.15252/embj.2020105380 · DOI
  23. Norris, 2015, Human prefrontal cortex phospholipids containing docosahexaenoic acid increase during normal adult aging, whereas those containing arachidonic acid decrease, Neurobiol. Aging, 36, 1659, 10.1016/j.neurobiolaging.2015.01.002 · DOI
  24. Prasad, 1998, Regional membrane phospholipid alterations in Alzheimer's disease, Neurochem. Res., 23, 81, 10.1023/A:1022457605436 · DOI
  25. Ginsberg, 1995, Disease and anatomic specificity of ethanolamine plasmalogen deficiency in Alzheimer's disease brain, Brain Res., 698, 223, 10.1016/0006-8993(95)00931-F · DOI
  26. Stokes, 1987, Reduced phosphoinositide concentrations in anterior temporal cortex of Alzheimer-diseased brains, J. Neurochem., 48, 1018, 10.1111/j.1471-4159.1987.tb05619.x · DOI · Paper page
  27. Reddan, 2018, Glycerophospholipid supplementation as a potential intervention for supporting cerebral structure in older adults, Front Aging Neurosci., 10, 49, 10.3389/fnagi.2018.00049 · DOI
  28. Qu, 2016, Docosahexaenoic acid-phosphatidylcholine improves cognitive deficits in an Abeta23-35-Induced Alzheimer's Disease rat model, Curr. Top Med. Chem., 16, 558, 10.2174/1568026615666150813144437 · DOI
  29. Tremblay, 2016, Remodeling of lipid bodies by docosahexaenoic acid in activated microglial cells, J. Neuroinflammation, 13, 116, 10.1186/s12974-016-0580-0 · DOI · Paper page
  30. Lin, 2024, Arachidonic acid mobilization and peroxidation promote microglial dysfunction in abeta pathology, J. Neurosci., 44, 10.1523/JNEUROSCI.0202-24.2024 · DOI
  31. van Meer, 2008, Membrane lipids: where they are and how they behave, Nat. Rev. Mol. Cell Biol., 9, 112, 10.1038/nrm2330 · DOI · Paper page
  32. Zheng, 2021, An imbalanced ratio between PC(16:0/16:0) and LPC(16:0) revealed by lipidomics supports the role of the Lands cycle in ischemic brain injury, J. Biol. Chem., 296, 10.1074/jbc.RA120.016565 · DOI
  33. Yung, 2015, Lysophosphatidic Acid signaling in the nervous system, Neuron, 85, 669, 10.1016/j.neuron.2015.01.009 · DOI
  34. Zhang, 2021, The structural basis for the phospholipid remodeling by lysophosphatidylcholine acyltransferase 3, Nat. Commun., 12, 6869, 10.1038/s41467-021-27244-1 · DOI
  35. Scholz, 2017, Lysophosphatidylcholine activates caspase-1 in microglia via a novel pathway involving two inflammasomes, J. Neuroimmunol., 310, 107, 10.1016/j.jneuroim.2017.07.004 · DOI
  36. Blank, 2022, LPS-induced lipid alterations in microglia revealed by MALDI mass spectrometry-based cell fingerprinting in neuroinflammation studies, Sci. Rep., 12, 2908, 10.1038/s41598-022-06894-1 · DOI
  37. Geraldo, 2021, Role of lysophosphatidic acid and its receptors in health and disease: novel therapeutic strategies, Signal. Transduct. Target. Ther., 6, 45, 10.1038/s41392-020-00367-5 · DOI
  38. Semba, 2020, Perspective: the potential role of circulating lysophosphatidylcholine in neuroprotection against alzheimer disease, Adv. Nutr., 11, 760, 10.1093/advances/nmaa024 · DOI
  39. Morell, 1996, Origin of cholesterol in myelin, Neurochem. Res., 21, 463, 10.1007/BF02527711 · DOI
  40. Feringa, 2024, The Neurolipid Atlas: a lipidomics resource for neurodegenerative diseases uncovers cholesterol as a regulator of astrocyte reactivity impaired by ApoE4, bioRxiv.
  41. Xiao, 2024, 25-Hydroxycholesterol regulates lysosome AMP kinase activation and metabolic reprogramming to educate immunosuppressive macrophages, Immunity, 57, 1087, 10.1016/j.immuni.2024.03.021 · DOI
  42. Asano, 2023, Serum 25-hydroxycholesterol levels are increased in patients with coronavirus disease 2019, J. Clin. Lipidol., 17, 78, 10.1016/j.jacl.2022.10.012 · DOI
  43. Zhou, 2020, Human and mouse single-nucleus transcriptomics reveal TREM2-dependent and TREM2-independent cellular responses in Alzheimer's disease, Nat. Med., 26, 131, 10.1038/s41591-019-0695-9 · DOI · Paper page
  44. Romero, 2024, 25-hydroxycholesterol promotes brain cytokine production and leukocyte infiltration in a mouse model of lipopolysaccharide-induced neuroinflammation, J. Neuroinflammation, 21, 251, 10.1186/s12974-024-03233-1 · DOI
  45. Choi, 2025, 25-Hydroxycholesterol modulates microglial function and exacerbates Alzheimer's disease pathology: mechanistic insights and therapeutic potential of cholesterol esterification inhibition, J. Neuroinflammation, 22, 50, 10.1186/s12974-025-03357-y · DOI
  46. Saher, 2023, Cholesterol metabolism in aging and age-related disorders, Annu. Rev. Neurosci., 46, 59, 10.1146/annurev-neuro-091922-034237 · DOI
  47. Tilvis, 2011, Prognostic significance of serum cholesterol, lathosterol, and sitosterol in old age; a 17-year population study, Ann. Med., 43, 292, 10.3109/07853890.2010.546363 · DOI
  48. Ward, 2019, Statin toxicity, Circ. Res., 124, 328, 10.1161/CIRCRESAHA.118.312782 · DOI
  49. Cantuti-Castelvetri, 2018, Defective cholesterol clearance limits remyelination in the aged central nervous system, Science, 359, 684, 10.1126/science.aan4183 · DOI · Paper page
  50. Bie, 2025, An unraveled mystery: what's the role of brain sphingolipids in neurodegenerative and psychiatric disorders, Neurobiol. Dis., 207, 10.1016/j.nbd.2025.106852 · DOI
  51. Huynh, 2020, Concordant peripheral lipidome signatures in two large clinical studies of Alzheimer's disease, Nat. Commun., 11, 5698, 10.1038/s41467-020-19473-7 · DOI · Paper page
  52. Schneider, 2019, Sphingomyelin in brain and cognitive development: preliminary data, eNeuro, 6, 10.1523/ENEURO.0421-18.2019 · DOI
  53. Cutler, 2004, Involvement of oxidative stress-induced abnormalities in ceramide and cholesterol metabolism in brain aging and Alzheimer's disease, Proc. Natl. Acad. Sci. U. S. A., 101, 2070, 10.1073/pnas.0305799101 · DOI · Paper page
  54. McInnis, 2024, Unravelling neuronal and glial differences in ceramide composition, synthesis, and sensitivity to toxicity, Commun. Biol., 7, 1597, 10.1038/s42003-024-07231-0 · DOI
  55. Cohn, 2021, Multi-Omics analysis of microglial extracellular vesicles from human Alzheimer's Disease brain tissue reveals disease-associated signatures, Front Pharmacol., 12, 10.3389/fphar.2021.766082 · DOI
  56. Gouwens, 2018, Abeta42 protofibrils interact with and are trafficked through microglial-derived microvesicles, ACS Chem. Neurosci., 9, 1416, 10.1021/acschemneuro.8b00029 · DOI
  57. Joshi, 2014, Microglia convert aggregated amyloid-beta into neurotoxic forms through the shedding of microvesicles, Cell Death Differ., 21, 582, 10.1038/cdd.2013.180 · DOI
  58. Karunakaran, 2019, Neural sphingosine 1-phosphate accumulation activates microglia and links impaired autophagy and inflammation, Glia, 67, 1859, 10.1002/glia.23663 · DOI
  59. Jung, 2023, Dysregulation of sphingosine-1-phosphate (S1P) and S1P receptor 1 signaling in the 5xFAD mouse model of Alzheimer's disease, Brain Res., 1799, 10.1016/j.brainres.2022.148171 · DOI
  60. Zhu, 2023, The S1P receptor 1 antagonist Ponesimod reduces TLR4-induced neuroinflammation and increases Abeta clearance in 5XFAD mice, EBioMedicine, 94, 10.1016/j.ebiom.2023.104713 · DOI
  61. Jung, 2025, ApoM-bound S1P acts via endothelial S1PR1 to suppress choroidal neovascularization and vascular leakage, Angiogenesis, 28, 24, 10.1007/s10456-025-09975-7 · DOI
  62. Prakash, 2024, Amyloid beta induces lipid droplet-mediated microglial dysfunction in Alzheimer's Disease, bioRxiv
  63. Kanter, 2012, Acyl-CoA synthetase 1 is required for oleate and linoleate mediated inhibition of cholesterol efflux through ATP-binding cassette transporter A1 in macrophages, Biochim. Biophys. Acta, 1821, 358, 10.1016/j.bbalip.2011.10.008 · DOI
  64. Ellis, 2010, Adipose acyl-CoA synthetase-1 directs fatty acids toward beta-oxidation and is required for cold thermogenesis, Cell Metab., 12, 53, 10.1016/j.cmet.2010.05.012 · DOI
  65. Nagga, 2018, Increased midlife triglycerides predict brain beta-amyloid and tau pathology 20 years later, Neurology, 90, e73, 10.1212/WNL.0000000000004749 · DOI
  66. Feingold, 2022, Lipid and lipoprotein metabolism, Endocrinol. Metab. Clin. North Am., 51, 437, 10.1016/j.ecl.2022.02.008 · DOI
  67. Koch, 2001, Characterization of four lipoprotein classes in human cerebrospinal fluid, J. Lipid Res., 42, 1143, 10.1016/S0022-2275(20)31605-9 · DOI · Paper page
  68. Pitas, 1998, Role of apolipoprotein E in modulating neurite outgrowth: potential effect of intracellular apolipoprotein E, Biochem. Soc. Trans., 26, 257, 10.1042/bst0260257 · DOI
  69. Roheim, 1979, Apolipoproteins in human cerebrospinal fluid, Proc. Natl. Acad. Sci. U. S. A., 76, 4646, 10.1073/pnas.76.9.4646 · DOI · Paper page
  70. Rueda, 2017, High density lipoproteins selectively promote the survival of human regulatory T cells, J. Lipid Res., 58, 1514, 10.1194/jlr.M072835 · DOI
  71. Timmerman, 1996, Differential expression of complement components in human fetal and adult kidneys, Kidney Int., 49, 730, 10.1038/ki.1996.102 · DOI
  72. Fryirs, 2010, Effects of high-density lipoproteins on pancreatic beta-cell insulin secretion, Arterioscler. Thromb. Vasc. Biol., 30, 1642, 10.1161/ATVBAHA.110.207373 · DOI
  73. Navab, 2000, Normal high density lipoprotein inhibits three steps in the formation of mildly oxidized low density lipoprotein: steps 2 and 3, J. Lipid Res., 41, 1495, 10.1016/S0022-2275(20)33462-3 · DOI
  74. Davidson, 2021, The difference between high density lipoprotein subfractions and subspecies: an evolving model in cardiovascular disease and diabetes, Curr. Atheroscler. Rep., 23, 23, 10.1007/s11883-021-00925-4 · DOI
  75. Tsujita, 2024, Lipoprotein particles in cerebrospinal fluid, Arterioscler. Thromb. Vasc. Biol., 44, 1042, 10.1161/ATVBAHA.123.318284 · DOI · Paper page
  76. Ward, 2012, Prevalence of apolipoprotein E4 genotype and homozygotes (APOE e4/4) among patients diagnosed with Alzheimer's disease: a systematic review and meta-analysis, Neuroepidemiology, 38, 1, 10.1159/000334607 · DOI · Paper page
  77. Levi, 2003, ApoE4 impairs hippocampal plasticity isoform-specifically and blocks the environmental stimulation of synaptogenesis and memory, Neurobiol. Dis., 13, 273, 10.1016/S0969-9961(03)00045-7 · DOI
  78. Feringa, 2024, An inside job: new roles for ApoE at the lipid droplet, J. Cell Biol., 223, 10.1083/jcb.202402171 · DOI
  79. Blumenfeld, 2024, Cell type-specific roles of APOE4 in Alzheimer disease, Nat. Rev. Neurosci., 25, 91, 10.1038/s41583-023-00776-9 · DOI · Paper page
  80. Friday, 2024, APOE4 alters the lipid droplet proteome and modulates droplet dynamics, bioRxiv
  81. Stukas, 2014, Intravenously injected human apolipoprotein A-I rapidly enters the central nervous system via the choroid plexus, J. Am. Heart. Assoc., 3, 10.1161/JAHA.114.001156 · DOI
  82. Tsujita, 2021, Apolipoprotein A-I in mouse cerebrospinal fluid derives from the liver and intestine via plasma high-density lipoproteins assembled by ABCA1 and LCAT, FEBS Lett., 595, 773, 10.1002/1873-3468.13950 · DOI
  83. Nissen, 2005, Effect of intensive lipid lowering on progression of coronary atherosclerosis: evidence for an early benefit from the Reversal of Atherosclerosis with Aggressive Lipid Lowering (REVERSAL) trial, Am. J. Cardiol., 96, 61F, 10.1016/j.amjcard.2005.07.013 · DOI
  84. Vanherle, 2022, The ApoA-I mimetic peptide 5A enhances remyelination by promoting clearance and degradation of myelin debris, Cell Rep., 41, 10.1016/j.celrep.2022.111591 · DOI · Paper page
  85. Lu, 2024, Circulatory proteins shape microglia state and boost phagocytosis, bioRxiv
  86. Fung, 2024, Apolipoprotein A1 and high-density lipoprotein limit low-density lipoprotein transcytosis by binding SR-B1, J. Lipid Res., 65, 10.1016/j.jlr.2024.100530 · DOI
  87. Husemann, 2002, Scavenger receptors in neurobiology and neuropathology: their role on microglia and other cells of the nervous system, Glia, 40, 195, 10.1002/glia.10148 · DOI
  88. Thanopoulou, 2010, Scavenger receptor class B type I (SR-BI) regulates perivascular macrophages and modifies amyloid pathology in an Alzheimer mouse model, Proc. Natl. Acad. Sci. U. S. A., 107, 20816, 10.1073/pnas.1005888107 · DOI · Paper page
  89. Slot, 2017, Apolipoprotein A1 in cerebrospinal fluid and plasma and progression to Alzheimer's Disease in non-demented elderly, J. Alzheimers Dis., 56, 687, 10.3233/JAD-151068 · DOI
  90. De Schepper, 2023, Perivascular cells induce microglial phagocytic states and synaptic engulfment via SPP1 in mouse models of Alzheimer's disease, Nat. Neurosci., 26, 406, 10.1038/s41593-023-01257-z · DOI · Paper page
  91. Cooke, 2018, A thumbwheel mechanism for APOA1 activation of LCAT activity in HDL, J. Lipid Res., 59, 1244, 10.1194/jlr.M085332 · DOI · Paper page
  92. Wei, 2024, TREM2 regulates microglial lipid droplet formation and represses post-ischemic brain injury, Biomed. Pharmacother., 170, 10.1016/j.biopha.2023.115962 · DOI · Paper page
  93. Filipello, 2023, Defects in lysosomal function and lipid metabolism in human microglia harboring a TREM2 loss of function mutation, Acta Neuropathol., 145, 749, 10.1007/s00401-023-02568-y · DOI · Paper page
  94. Wang, 2024, Integrative metabolomics and whole transcriptome sequencing reveal role for TREM2 in metabolism homeostasis in Alzheimer's Disease, Mol. Neurobiol., 61, 4188, 10.1007/s12035-023-03840-8 · DOI
  95. Petroula Proitsi, 2024, Alterations in the brain lipidome of alzheimer’s disease donors with rare TREM2 risk variantsmed, MedRxiv
  96. Vasilopoulou, 2025, Amelioration of signaling deficits underlying metabolic shortfall in TREM2(R47H) human iPSC-derived microglia, FEBS J., 292, 1743, 10.1111/febs.17353 · DOI
  97. van Lengerich, 2023, A TREM2-activating antibody with a blood-brain barrier transport vehicle enhances microglial metabolism in Alzheimer's disease models, Nat. Neurosci., 26, 416
  98. Li, 2024, Boosting microglial lipid metabolism via TREM2 signaling by biomimetic nanoparticles to attenuate the sevoflurane-induced developmental neurotoxicity, Adv. Sci. (Weinh), 11
  99. Kang, 2024, Microglia undergo sex-dimorphic transcriptional and metabolic rewiring during aging, J. Neuroinflammation, 21, 150, 10.1186/s12974-024-03130-7 · DOI
  100. Ocanas, 2023, Microglial senescence contributes to female-biased neuroinflammation in the aging mouse hippocampus: implications for Alzheimer's disease, J. Neuroinflammation, 20, 188, 10.1186/s12974-023-02870-2 · DOI
  101. Hyde, 2025, Anti-herpetic tau preserves neurons via the cGAS-STING-TBK1 pathway in Alzheimer's disease, Cell Rep., 44, 10.1016/j.celrep.2024.115109 · DOI
  102. Niemeyer, 2024, Olfactory and trigeminal routes of HSV-1 CNS infection with regional microglial heterogeneity, J. Virol., 98, 10.1128/jvi.00968-24 · DOI
  103. Fruhwurth, 2023, TREM2 is down-regulated by HSV1 in microglia and involved in antiviral defense in the brain, Sci. Adv., 9, 10.1126/sciadv.adf5808 · DOI
  104. Hopp, 2023, Multi-omics analyses reveal novel effects of PLCgamma2 deficiency in the mouse brain, bioRxiv
  105. Gouna, 2021, TREM2-dependent lipid droplet biogenesis in phagocytes is required for remyelination, J. Exp. Med., 218, 10.1084/jem.20210227 · DOI · Paper page
  106. Kober, 2020, Functional insights from biophysical study of TREM2 interactions with apoE and Abeta1-42, Alzheimers Dement, 17, 475, 10.1002/alz.12194 · DOI
  107. Cleland, 2024, Fatty acid sensing in the brain: the role of glial-neuronal metabolic crosstalk and horizontal lipid flux, Biochimie, 223, 166, 10.1016/j.biochi.2022.08.012 · DOI
  108. Gildea, 2025, Mechanisms of astrocyte aging in reactivity and disease, Mol. Neurodegener., 20, 21, 10.1186/s13024-025-00810-7 · DOI · Paper page
  109. Leng, 2022, Author Correction: microglial hexokinase 2 deficiency increases ATP generation through lipid metabolism leading to beta-amyloid clearance, Nat. Metab., 4, 1420, 10.1038/s42255-022-00682-x · DOI
  110. van Olst, 2025, Microglial mechanisms drive amyloid-beta clearance in immunized patients with Alzheimer’s disease, Nat. Med., 31, 1604, 10.1038/s41591-025-03574-1 · DOI
  111. Hu, 2022, Transcriptome-wide association study reveals cholesterol metabolism gene Lpl is a key regulator of cognitive dysfunction, Front Mol. Neurosci., 15, 10.3389/fnmol.2022.1044022 · DOI
  112. Li, 2024, ANGPTL4-mediated microglial lipid droplet accumulation: bridging Alzheimer's disease and obesity, Neurobiol. Dis., 203, 10.1016/j.nbd.2024.106741 · DOI
  113. Oldham, 2022, Using synthetic ApoC-II peptides and nAngptl4 fragments to measure lipoprotein lipase activity in radiometric and fluorescent assays, Front Cardiovasc. Med., 9, 10.3389/fcvm.2022.926631 · DOI
  114. Konaklieva, 2024, Targeting host-specific metabolic pathways-opportunities and challenges for anti-infective therapy, Front Mol. Biosci., 11, 10.3389/fmolb.2024.1338567 · DOI
  115. Dabravolski, 2024, The role of lipase maturation factor 1 in hypertriglyceridaemia and atherosclerosis: an update, SAGE Open Med., 12, 10.1177/20503121241289828 · DOI
  116. Heidemann, 2022, Clinical heterogeneity in monogenic chylomicronaemia, BMJ Case Rep., 15, 10.1136/bcr-2022-251411 · DOI
  117. Whitacre, 2022, Apolipoprotein E content of VLDL limits LPL-mediated triglyceride hydrolysis, J. Lipid Res., 63, 10.1016/j.jlr.2021.100157 · DOI
  118. Wu, 2021, Rare novel LPL mutations are associated with neonatal onset lipoprotein lipase (LPL) deficiency in two cases, BMC Pediatr., 21, 414, 10.1186/s12887-021-02875-x · DOI
  119. Wu, 2023, Loss-of-Function homozygous variant in LPL causes type I hyperlipoproteinemia and renal lipidosis, Kidney Int. Rep., 8, 2428, 10.1016/j.ekir.2023.08.027 · DOI
  120. Azmoon, 2024, LRP1 triggers pro-inflammatory cell-signaling in response to extracellular Tau independently of the NMDA receptor, bioRxiv
  121. Kang Chen, 2024, Single-cell data unveil the multifaceted role of LRP1 in alzheimer’s disease pathogenesis, Res. Square
  122. Ju, 2023, Andrographolide exerts a neuroprotective effect by regulating the LRP1-mediated PPARgamma/NF-kappaB pathway, Eur. J. Pharmacol., 951, 10.1016/j.ejphar.2023.175756 · DOI
  123. Jiao, 2022, Ginsenoside compound K acts via LRP1 to alleviate Amyloid beta(42)-induced neuroinflammation in microglia by suppressing NF-kappaB, Biochem. Biophys. Res. Commun., 590, 14, 10.1016/j.bbrc.2021.12.071 · DOI
  124. Mantuano, 2023, An LRP1-binding motif in cellular prion protein replicates cell-signaling activities of the full-length protein, JCI Insight, 8, 10.1172/jci.insight.170121 · DOI
  125. Mattei, 2020, A multimolecular signaling complex including PrP(C) and LRP1 is strictly dependent on lipid rafts and is essential for the function of tissue plasminogen activator, J. Neurochem., 152, 468, 10.1111/jnc.14891 · DOI
  126. Zhai, 2024, Repeated trans-spinal magnetic stimulation promotes microglial phagocytosis of myelin debris after spinal cord injury through LRP-1, Exp. Neurol., 379, 10.1016/j.expneurol.2024.114844 · DOI
  127. Yang, 2022, Activation of LRP1 ameliorates cerebral Ischemia/Reperfusion Injury and cognitive decline by suppressing neuroinflammation and oxidative stress through TXNIP/NLRP3 signaling pathway in mice, Oxid Med. Cell Longev., 2022, 10.1155/2022/8729398 · DOI
  128. Kaye, 2025, Hypercholesterolemia drives microglial dysfunction and weakens response to amyloid plaques, Exp. Neurol., 390, 10.1016/j.expneurol.2025.115272 · DOI
  129. Park, 2021, Microglial MERTK eliminates phosphatidylserine-displaying inhibitory post-synapses, EMBO J., 40, 10.15252/embj.2020107121 · DOI
  130. Fan, 2023, Associations of circulating saturated long-chain fatty acids with risk of mild cognitive impairment and Alzheimer’s disease in the Alzheimer’s Disease Neuroimaging Initiative (ADNI) cohort, BioMedicine, 97, 104818
  131. Cisbani, 2021, Murine and human microglial cells are relatively enriched with eicosapentaenoic acid compared to the whole brain, Neurochem. Int., 150, 105154, 10.1016/j.neuint.2021.105154 · DOI
  132. Morris, 2003, Dietary fats and the risk of incident Alzheimer’s disease, Arch. Neurol., 60, 194, 10.1001/archneur.60.2.194 · DOI
  133. Yu, 2024, Palmitoleic acid protects microglia from palmitate-induced neurotoxicity in vitro, PLoS One, 19
  134. Oh, 2009, Oleic acid reduces lipopolysaccharide-induced expression of iNOS and COX-2 in BV2 murine microglial cells: possible involvement of reactive oxygen species, p38 MAPK, and IKK/NF-kappaB signaling pathways, Neurosci. Lett., 464, 93, 10.1016/j.neulet.2009.08.040 · DOI
  135. Hamilton, 2022, Stearoyl-CoA Desaturase inhibition reverses immune, synaptic and cognitive impairments in an Alzheimer’s disease mouse model, Nat, Commun., 13, 2061, 10.1038/s41467-022-29506-y · DOI
  136. Devassy, 2016, Omega-3 Polyunsaturated Fatty Acids and Oxylipins in Neuroinflammation and Management of Alzheimer’s Disease, Adv. Nutr., 7, 905, 10.3945/an.116.012187 · DOI
  137. Hopperton, 2016, Brain omega-3 polyunsaturated fatty acids modulate microglia cell number and morphology in response to intracerebroventricular amyloid-beta 1-40 in mice, J. Neuroinflammation, 13, 257, 10.1186/s12974-016-0721-5 · DOI
  138. Ates, 2020, CMS121, a fatty acid synthase inhibitor, protects against excess lipid peroxidation and inflammation and alleviates cognitive loss in a transgenic mouse model of Alzheimer’s disease, Redox Biol., 36, 101648, 10.1016/j.redox.2020.101648 · DOI
  139. Shepardson, 2011, Cholesterol level and statin use in Alzheimer disease: II. Review of human trials and recommendations, Arch. Neurol., 68, 1385, 10.1001/archneurol.2011.242 · DOI
  140. Qiu, 2023, Definition of the contribution of an Osteopontin-producing CD11c(+) microglial subset to Alzheimer’s disease, Proc. Natl. Acad. Sci. U. S. A., 120, 10.1073/pnas.2218915120 · DOI

Cited by

Sorted by citations

Metadata

Authors
Sprenger, K. G., Lietzke, E. E., Melchior, J. T., & Bruce, K. D.
Venue
Journal of Lipid Research
Publisher
Elsevier BV
Published
2025-10
Volume
66
Issue
10
Pages
100872
ISSN
0022-2275
DOI
10.1016/j.jlr.2025.100872
PMC
PMC12538436
Cited by
42
References
43
Language
en
Licence
Funders
  • National Institute of Neurological Disorders and Stroke
  • National Institute on Aging

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review